Neurotech Releases ESG Report Amid Clinical Advances

Neurotech International Ltd. (AU:NTI) has released an update.

Neurotech International Ltd, a clinical-stage biopharmaceutical company, has published its Environmental Social Governance Report, emphasizing its commitment to ESG principles and their importance in the company’s long-term success and sustainability. The report aligns with the World Economic Forum’s core metrics and highlights Neurotech’s efforts to attract responsible investors and mitigate ESG-related risks. The company, which specializes in paediatric neurological disorders, has also reported positive results from clinical trials of its oral cannabinoid drug therapy for various conditions.

For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.